USD 3.75
(0.81%)
Year | Gross Profit | Gross Profit Growth |
---|---|---|
2023 | -303 Thousand USD | -122.75% |
2022 | 1.33 Million USD | -81.35% |
2021 | 7.14 Million USD | 123.99% |
2020 | 3.18 Million USD | -21.57% |
2019 | 4.06 Million USD | 525.76% |
2018 | -955 Thousand USD | -48.52% |
2017 | -643 Thousand USD | -116.5% |
2016 | -297 Thousand USD | -760.0% |
2015 | 45 Thousand USD | 0.0% |
Year | Gross Profit | Gross Profit Growth |
---|---|---|
2024 Q2 | -61 Thousand USD | 7.58% |
2024 Q1 | -66 Thousand USD | 0.0% |
2023 Q4 | - USD | 100.0% |
2023 FY | -303 Thousand USD | -122.75% |
2023 Q1 | -87 Thousand USD | 93.47% |
2023 Q2 | -77 Thousand USD | 11.49% |
2023 Q3 | -157 Thousand USD | -103.9% |
2022 Q4 | -1.33 Million USD | -425.67% |
2022 FY | 1.33 Million USD | -81.35% |
2022 Q2 | 326 Thousand USD | -45.39% |
2022 Q3 | 409 Thousand USD | 25.46% |
2022 Q1 | 597 Thousand USD | 36.3% |
2021 Q1 | 2.51 Million USD | 185.67% |
2021 Q3 | 2.15 Million USD | 6.09% |
2021 Q4 | 438 Thousand USD | -79.71% |
2021 FY | 7.14 Million USD | 123.99% |
2021 Q2 | 2.03 Million USD | -18.96% |
2020 FY | 3.18 Million USD | -21.57% |
2020 Q4 | 879 Thousand USD | -42.13% |
2020 Q3 | 1.51 Million USD | 1952.7% |
2020 Q2 | 74 Thousand USD | -89.68% |
2020 Q1 | 717 Thousand USD | 65.59% |
2019 Q3 | 783 Thousand USD | -54.08% |
2019 Q2 | 1.7 Million USD | 48.91% |
2019 Q1 | 1.14 Million USD | 0.0% |
2019 FY | 4.06 Million USD | 525.76% |
2019 Q4 | 433 Thousand USD | -44.7% |
2018 Q2 | - USD | 0.0% |
2018 Q3 | - USD | 0.0% |
2018 FY | -955 Thousand USD | -48.52% |
2018 Q1 | - USD | 0.0% |
2018 Q4 | - USD | 0.0% |
2017 Q4 | - USD | 0.0% |
2017 Q1 | - USD | 0.0% |
2017 Q2 | - USD | 0.0% |
2017 Q3 | - USD | 0.0% |
2017 FY | -643 Thousand USD | -116.5% |
2016 Q4 | - USD | 0.0% |
2016 Q2 | - USD | 0.0% |
2016 FY | -297 Thousand USD | -760.0% |
2016 Q1 | - USD | 0.0% |
2016 Q3 | - USD | 0.0% |
2015 FY | 45 Thousand USD | 0.0% |
Name | Gross Profit | Gross Profit Difference |
---|---|---|
ANI Pharmaceuticals, Inc. | 305.3 Million USD | 100.099% |
Aquestive Therapeutics, Inc. | 29.75 Million USD | 101.018% |
Collegium Pharmaceutical, Inc. | 326.16 Million USD | 100.093% |
Cosmos Health Inc. | 4.34 Million USD | 106.966% |
Cyclo Therapeutics, Inc. | -2.41 Million USD | 87.428% |
Esperion Therapeutics, Inc. | 73.06 Million USD | 100.415% |
Cronos Group Inc. | 6.99 Million USD | 104.334% |
Incannex Healthcare Limited | 12 Thousand USD | 2625.0% |
Lifecore Biomedical, Inc. | 41.85 Million USD | 100.724% |
Regencell Bioscience Holdings Limited | -745.58 Thousand USD | 59.361% |
Sunshine Biopharma, Inc. | 8.33 Million USD | 103.633% |
Sunshine Biopharma, Inc. | 8.33 Million USD | 103.633% |
SCYNEXIS, Inc. | 124.51 Million USD | 100.243% |
Safety Shot Inc | -74.45 Thousand USD | -306.946% |
Theratechnologies Inc. | 62.12 Million USD | 100.488% |
Alpha Teknova, Inc. | 10.29 Million USD | 102.943% |
Universe Pharmaceuticals INC | 10.07 Million USD | 103.007% |
Pacira BioSciences, Inc. | 490.3 Million USD | 100.062% |
Sonoma Pharmaceuticals, Inc. | 4.74 Million USD | 106.386% |
Dynavax Technologies Corporation | 182.11 Million USD | 100.166% |
Ironwood Pharmaceuticals, Inc. | 441.16 Million USD | 100.069% |
Radius Health, Inc. | 307.71 Million USD | 100.098% |
China SXT Pharmaceuticals, Inc. | 553.97 Thousand USD | 154.696% |
Alvotech | -69.42 Million USD | 99.564% |
Intra-Cellular Therapies, Inc. | 430.62 Million USD | 100.07% |
SIGA Technologies, Inc. | 122.09 Million USD | 100.248% |
Shineco, Inc. | 882.16 Thousand USD | 134.347% |
Silver Spike Investment Corp. | 8.1 Million USD | 103.74% |
Journey Medical Corporation | 52.52 Million USD | 100.577% |
Petros Pharmaceuticals, Inc. | 4.19 Million USD | 107.229% |
Embecta Corp. | 749.9 Million USD | 100.04% |
Harrow Health, Inc. | 90.55 Million USD | 100.335% |
Procaps Group, S.A. | 239.56 Million USD | 100.126% |
Biofrontera Inc. | 16.62 Million USD | 101.822% |
DURECT Corporation | 6.83 Million USD | 104.436% |
PainReform Ltd. | -15 Thousand USD | -1920.0% |
Supernus Pharmaceuticals, Inc. | 523.74 Million USD | 100.058% |
OptiNose, Inc. | 62.35 Million USD | 100.486% |
RedHill Biopharma Ltd. | 3.05 Million USD | 109.921% |
Organogenesis Holdings Inc. | 309.79 Million USD | 100.098% |
Cumberland Pharmaceuticals Inc. | 33.48 Million USD | 100.905% |
ProPhase Labs, Inc. | 16.23 Million USD | 101.866% |
Phibro Animal Health Corporation | 312.48 Million USD | 100.097% |
Procaps Group S.A. | 239.56 Million USD | 100.126% |
TherapeuticsMD, Inc. | 1.3 Million USD | 123.272% |
Viatris Inc. | 6.43 Billion USD | 100.005% |
Rockwell Medical, Inc. | 8.7 Million USD | 103.481% |
Aytu BioPharma, Inc. | 54.58 Million USD | 100.555% |
Tilray Brands, Inc. | 223.35 Million USD | 100.136% |
PetIQ, Inc. | 252.74 Million USD | 100.12% |
Talphera, Inc. | -4.89 Million USD | 93.81% |
Neurocrine Biosciences, Inc. | 1.84 Billion USD | 100.016% |
Alimera Sciences, Inc. | 61.17 Million USD | 100.495% |
Assertio Holdings, Inc. | 125.04 Million USD | 100.242% |
Shuttle Pharmaceuticals Holdings, Inc. | -6811.00 USD | -4348.686% |
Avadel Pharmaceuticals plc | 27.11 Million USD | 101.117% |
Hempacco Co., Inc. | -1.21 Million USD | 75.079% |
Alvotech | -69.42 Million USD | 99.564% |
Lantheus Holdings, Inc. | 709.54 Million USD | 100.043% |
Kamada Ltd. | 52.59 Million USD | 100.576% |
Currenc Group, Inc. | 17.35 Million USD | 101.746% |
Indivior PLC | 907 Million USD | 100.033% |
Evoke Pharma, Inc. | 4.97 Million USD | 106.086% |
Flora Growth Corp. | 17.73 Million USD | 101.708% |
Cyclo Therapeutics, Inc. | -2.41 Million USD | 87.428% |
Evolus, Inc. | 140.52 Million USD | 100.216% |
HUTCHMED (China) Limited | 453.55 Million USD | 100.067% |
Amphastar Pharmaceuticals, Inc. | 343.96 Million USD | 100.088% |
Akanda Corp. | 111.44 Thousand USD | 371.873% |